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Abstract
Background: Catheter ablation of the pulmonary veins has become accepted as a standard therapeutic approach
for symptomatic paroxysmal atrial fibrillation (AF). However, there is some evidence for an ablation associated
(silent) stroke risk, lowering the hope to limit the stroke risk by restoration of rhythm over rate control in AF. The
purpose of the prospective randomized single-center study “Mesh Ablator versus Cryoballoon Pulmonary Vein
Ablation of Symptomatic Paroxysmal Atrial Fibrillation” (MACPAF) is to compare the efficacy and safety of two
balloon based pulmonary vein ablation systems in patients with symptomatic paroxysmal AF.
Methods/Design: Patients are randomized 1:1 for the Arctic Front® or the HD Mesh Ablator® catheter for left atrial
catheter ablation (LACA). The predefined endpoints will be assessed by brain magnetic resonance imaging (MRI),
neuro(psycho)logical tests and a subcutaneously implanted reveal recorder for AF detection. According to statistics
108 patients will be enrolled.
Discussion: Findings from the MACPAF trial will help to balance the benefits and risks of LACA for symptomatic
paroxysmal AF. Using serial brain MRIs might help to identify patients at risk for LACA-associated cerebral
thromboembolism. Potential limitations of the study are the single-center design, the existence of a variety of
LACA-catheters, the missing placebo-group and the impossibility to assess the primary endpoint in a blinded
fashion.
Trial registration: clinicaltrials.gov NCT01061931
Background
About 20-37% of all ischemic strokes are of cardio-
embolic origin [1,2], caused by different cardiac disor-
ders, but most commonly by atrial fibrillation (AF). The
current demographic trends will lead to an increasing
prevalence of AF [3,4] and implicate a growing risk of
cardioembolic stroke [1]. In general, cardioembolic
stroke has a worse prognosis and a higher recurrence
rate than other ischemic stroke subtypes [5]. According
to recent guidelines, the left atrial catheter ablation
(LACA) of pulmonary veins (PV) is approved for treat-
ment of symptomatic atrial fibrillation (AF) in patients
with paroxysmal or persistent AF, refractory to
antiarrhythmic medication [6]. Within the last years,
LACA using radiofrequency has become a routine pro-
cedure and is widely used [7]. In patients with paroxy-
smal AF (<65 years) and without structural heart disease
the achieved rate of persisting sinus rhythm is best and
varies between 60% and 80% [8,9]. Major complications
like pericardial tamponade, PV-stenosis, atrial-esopha-
geal fistula, injury of the phrenic nerve and vascular
damage by atrial and venous sheaths were detected
more often in older patients (≥75 years) and patients
with congestive heart failure [10]. Furthermore, there is
some evidence for an ablation associated stroke risk
[9,11,12], lowering the (so far) unproven hope to limit
the AF-associated stroke risk by LACA. Considering
that most AF patients “eligible” for LACA have a low
stroke risk [13], the evident stroke rate of 0.4-1.1% in
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11.3% [14,15] raise concerns and afford further
investigation.
As demonstrated in humans, a balloon catheter using
cryoenergy (Arctic Front®, Medtronic, Inc.) had safety
advantages compared to radiofrequency devices [16].
Another basket shaped catheter device (HD Mesh abla-
tor®, C.R. Bard, Inc.) combines circumferential mapping
and radiofrequency delivery, leading to a reduced proce-
dure and fluoroscopy time [17]. Both catheters are
already used in daily clinical practice at the Department
of Cardiology, Charité Campus Benjamin Franklin
(CBF). Therefore, we designed a randomized single cen-
ter study to evaluate the risks and benefits of LACA,
using these innovative catheter devices.
Conducting MACPAF, we focus on the devices’ peri-
procedural (silent) stroke rates and subsequent neuro
(psycho)logical deficits. By us i n gah i g h l ys t a n d a r d i z e d
monitoring including serial brain magnetic resonance
imaging (MRI) and neuro(psycho)logical tests we hope
to set new standards for further trials in this regard.
Furthermore, the implanted reveal recorder Reveal XT®
(Medtronic, Inc.) is highly accurate to detect clinically
silent AF episodes, not infrequently occurring after
LACA [18] on the one hand, and to determine the AF
burden, on the other hand.
Methods/Design
Study population and study design
The Mesh Ablator versus Cryoballoon Pulmonary Vein
Ablation of Symptomatic Paroxysmal Atrial Fibrillation
(MACPAF) study is designed as a prospective rando-
mized single center study conducted by the Department
of Cardiology and Pneumology (Charité, CBF), the Cen-
ter for Stroke Research Berlin and the Department of
Neurology (Charité, CBF). The study has been approved
by the local Ethics Committee (EA4/087/08) in February
2009. Randomization started in April 2009. Study entry
and storage of data require subsequent consent by the
patient. The inclusion and exclusion criteria are sum-
marized in Table 1. Before undergoing LACA, patients
receive an implantable device (Reveal XT®, Medtronic,
Inc.) able to record the AF burden for at least 2 years.
Within 24 h before LACA, all patients undergo transe-
sophageal echocardiography (for exclusion of atrial
thrombi), a brain MRI as well as a neuro(psycho)logical
examination. A repeat brain MRI and neuro(psycho)
logical examination will be performed within 48 h after
the procedure. Patients will be randomized 1:1 for the
cryoenergy device (Arctic Front®) or the newest device
using conventional radiofrequency (HD Mesh ablator®).
Before PV ablation, a CT image will be performed and
segmented by CARTO Merge® (Biosense Webster, Inc.)
for visualization of PV anatomy. The LACA procedure
will be performed by first introducing a ring shaped
decapolar catheter via a single transseptal puncture.
Afterwards, this catheter will be exchanged for the cryo-
balloon catheter or the mesh ablator, respectively.
Finally, PV conduction will be re-evaluated by the deca-
polar catheter. In case of remaining PV conduction, the
ablation procedure will be continued until isolation of
all PVs is achieved. After transseptal puncture, heparin
will be given to assure an activated clotting time of
>300 s. Follow-ups will take place at 1, 3, 6, 9 and 12
months after LACA, including data acquisition from the
Reveal XT® or a 5-day-holter-ECG, respectively. Brain
MRI and neuro(psycho)logical examination will be
repeated after 6 months. The patient will be put on oral
anticoagulation (INR 2-3) for at least 6 months after
LACA to improve comparability of the results. The end
of study is expected for late 2011.
Aims and objectives
The primary objective of MACPAF is the efficacy of PV
isolation, defined by achieving an exit block for all PVs
per patient. We hypothesize that the cryoballoon cathe-
ter is more effective compared to the mesh ablator
catheter in this regard. This is the only objective, which
can not be assessed in a blinded fashion for the used
ablation catheter. The secondary objective is the detec-
tion of LACA-associated (silent) cerebral thromboembo-
lism by brain MRI and by neuro(psycho)logical
examination. Further objectives are the determination of
the AF recurrence rate after LACA using an implantable
device, the detection of non-neurological major compli-
cations after LACA and the detection of (silent) cerebral
thromboembolism within 6 months after LACA.
Sample size calculation and Statistical analysis
The primary endpoint for a patient is achieved when all
four pulmonary veins are isolated. We hypothesize that
Table 1 MACPAF: Inclusion and exclusion criteria
Inclusion criteria:
￿ Patients with ECG-documented symptomatic paroxysmal atrial
fibrillation
￿ At least one ineffective antiarrhythmic drug treatment
￿ Age ≥ 18 and ≤ 75 years
Exclusion criteria
￿ Previous ablation procedure for AF
￿ Cardiac surgery ≤ 3 months
￿ Left atrial diameter > 50 mm or ejection fraction < 35%
￿ Instable coronary artery disease or clinically relevant cardiac valve
insufficiency
￿ Hyperthyroidism, pregnancy or lactation
￿ Coumadin or heparin intolerance
￿ Concomitant disease with expected lifespan < 2 years
￿ Contraindications for MRI
￿ Acute cerebral infarction (DWI lesion) detected by brain MRI
before LACA
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Front® catheter is superior to the HD Mesh Ablator®
catheter. The null hypothesis of equal proportions of
successful outcomes for both methods will be tested by
the two-sided Fisher’s exact test at significance level
0.05. Assuming a proportion of 75% successful ablations
for the HD Mesh Ablation® catheter, sample sizes of 54
for both treatment groups achieve 80% power to detect
a 20% greater proportion of successes for the Arctic
Front® catheter. This corresponds to a proportion of
95% successful ablations for the Arctic Front® catheter -
ar e l a t i v ei m p r o v e m e n to f2 7 %f o rt h eA r c t i cF r o n t ®
catheter in comparison to the HD Mesh Ablator®
catheter.
An intention-to-treat analysis will be used to analyze
treatment differences concerning predefined outcome
measures. Treatment allocation will be done by gender-
stratified randomization. For all outcome variables
descriptive statistics will be collected. For quantitative
traits, we will compute absolute and relative frequencies.
In the case of continuous or quasi-continuous variables
with nearly symmetric distribution, we will compute
arithmetic mean, standard deviation, minimal and maxi-
mal values, otherwise median, quartiles, minimal and
maximal values. Fisher’s exact test will be used to com-
pare proportions for dichotomous outcomes between
independent groups or to test independency of two
dichotomous traits within a population. Hypotheses
about proportions for dichotomous outcomes within a
single group (one sample analysis) will be tested by the
binomial test. Assuming equal shaped distributions in
the two treatment groups for at least ordinal scaled out-
come variables group specific location parameters will
be compared by the t-test or the Mann-Whitney test,
respectively, depending on normality or non-normality
of the distribution. Analysis regarding time to first AF-
recurrence: Defining ‘no observed AF-recurrence
between 3 months after LACA and the end of follow-
up’ as ‘survival’, survival functions will be estimated by
the Kaplan-Meier method. The null hypothesis of equal
survival curves for the two treatment groups will be
tested by the Log-Rank test.
MRI analysis
MRI examination is performed if the patient is able to
give informed consent. Using a 3T MR scanner (Tim
Trio; Siemens AG, Erlangen, Germany) the following
sequences will be done 24 hours before as well as 24-48
hours after the ablation procedure: T2*-weighted ima-
ging to screen for intracranial hemorrhage; diffusion-
weighted magnetic resonance imaging (DWI) to assess
cerebral infarction; Fluid-attenuated inverse recovery
(FLAIR) to estimate microangiopathic lesions load and
to investigate the age of recent lesions; time-of-flight
MR-Angiography (TOF MRA) to detect vessel stenosis
or occlusion. Six month after LACA a third measure-
ment without TOF MRA will be performed to assess
the incidence of (silent) strokes by time. For sequence
parameters see [19]. Blinded MRI reading will be done
by a board certified neuroradiologist (JBF).
Neurological examination
The National Institute of Health Stroke Scale (NIHSS) is
a validated instrument used in many clinical trials to
assess neurological deficits of stroke patients [20]. The
NIHSS displays the subjects’ consciousness, the ability
to move limbs, the sensorium, speech, vision and eye
movements. The modified Rankin Scale (mRS) is used
to quantify the persisting handicap after stroke [21].
Neuropsychological examination
The neuropsychological assessment was designed to
assess important cognitive domains and includes the fol-
lowing tests: Trail Making Test A and B (information
processing and divided attention), the Stroop Test, the
Category and Letter Fluency Test (all three assessing
different aspects of executive functions) [22], the subtest
3 from the German Leistungsprüfsystem (reasoning)
[23], a German version of the Rey Auditory Verbal
Learning Test [24], the digit-span forward and backward
test from the Wechsler Memory Scale - Revised [22]
(verbal short-term and working memory), the German
Mehrfachwahl-Wortschatz-Intelligenztest (MWT-A
Test; educational level) [25] as well as the Rey-Oster-
rieth Complex Figure Test (visuo-spatial skills and visual
memory) [22].
Discussion
The pulmonary vein (PV) ablation in patients with
symptomatic paroxysmal atrial fibrillation (AF) has
received increasing attention over the last years and is
now a well-established therapeutic approach to limit
symptomatic paroxysmal AF [6,7]. The use of novel
catheter techniques gives reasons to expect better
safety and efficacy, but there is little clinical evidence
so far [16,17]. Performing MACPAF, we hypothesize
that the cryoenergy device (Arctic Front®) is superior
to the balloon based device using radiofrequency (HD
Mesh ablator®) with regard to efficacy and safety. Effi-
cacy of LACA will be assessed by achieving a complete
PV isolation as an acute effect, and by a lack of AF
recurrence after a blanking period of three months
(long-term efficacy), evaluated by an implantable
device able to detect AF.
Focusing on the safety of LACA, the use of diffusion-
weighted magnetic resonance imaging will precisely
detect (silent) cerebral infarction, as recently demon-
strated using a 1.5T MRI [15]. The use of a 3T MRI
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of stroke detection, while the detection of cerebral
hemorrhage, chronic lesions and brain vessel occlusion
is at least equal to 1.5T MRI [26]. Therefore, we expect
a higher rate of silent strokes than the reported 10-
11.3% [14,15]. Furthermore, the MACPAF study will
demonstrate if the incidence of clinically silent or clini-
cally evident strokes differs within the tested ablation
systems. Moreover, a retrospective analysis of MACPAF
might identify LACA procedure-independent risk fac-
tors, hopefully reducing LACA-associated stroke rate
according to optimized technical conditions and patient
selection. Using an implantable device for AF detection
and a follow-up MRI after 6 months, we will be able to
correlate the rate of (silent) strokes with the AF burden
in patients on oral anticoagulation.
According to a http://www.clinicaltrial.org search, the
MACPAF study meets highest technical standards. To
eliminate potential conflicts of interest, this is an investi-
gator-initiated clinical trial.
Nevertheless, the MACPAF study has its strengths and
limitations. Firstly, using two balloon based ablation sys-
tems, our results are not transferable to other LACA
procedures. Secondly, focusing on paroxysmal AF, we
are unable to address questions regarding persistent AF.
Thirdly, the assessment of the predefined endpoints is
blinded but the LACA procedure itself can not be done
in a blinded fashion. Fourth, the limited number of
patients might not allow correction for multiple testing.
Fifth, according to the study design, a placebo-arm is
not intended. The lack of a placebo arm is justified as
ablation is a clinically indicated procedure and thus
withholding any ablation would be unethical. Prospec-
tive multicenter studies will be needed to clarify these
important issues.
Taken together, MACPAF is a prospective randomized
single-center trial to compare the efficacy and safety of
LACA for paroxysmal AF using two balloon based
catheter techniques. Results from MACPAF will provide
important information helping cardiologists and neurol-
ogists to better counsel AF-patients concerning risks
and benefits of LACA. Doing MACPAF, we hope to
make a significant contribution to the evaluation of the
LACA-associated (silent) stroke risk, setting the stage
for stroke-risk reduction by improved technical condi-
tions and appropriate patient selection.
List of abbreviations
AF: atrial fibrillation; LACA: left atrial catheter ablation;
MRI: magnetic resonance imaging; MACPAF: Mesh
Ablator versus Cryoballoon Pulmonary Vein Ablation of
Symptomatic Paroxysmal Atrial Fibrillation Study; PV:
pulmonary veins.
Acknowledgements
We thank Dr. Ute Kopp (Department of Neurology, Charité - University
Medicine Berlin, Germany) for her advice regarding neuropsychological tests.
The project has received funding from the Federal Ministry of Education and
Research via the grant Center for Stroke Research Berlin (01 EO 0801). ME
receives support from the Volkswagen-Stiftung, Deutsche
Forschungsgemeinschaft and the Federal Ministry of Education and
Research.
Author details
1Department of Neurology, Charité - University Medicine Berlin, Germany.
2Center for Stroke Research, Charité, Berlin, Germany.
3Department of
Cardiology and Pneumology, Charité - University Medicine Berlin, Germany.
Authors’ contributions
All authors have read and approved the final manuscript. LK, AS, KGH, ME,
HPS and JBF initiated the study. LK and KGH wrote the study-protocol and
the manuscript. LK will do the patient inclusion, JU the neuropsychological
examination and KGH the neurological and the MRI examinations under
supervision of JBF. Blinded MRI reading will be done by JBF. PUH did and
will do the statistical calculations.
Competing interests
KGH reports lecture fees by Sanofi-Aventis and LK reports lecture fees by
Medtronic. ME reports receiving consulting, lecture, grant and/or advisory
board fees by BMS, Sanofi-Aventis, Boehringer-Ingelheim, Novartis, Pfizer and
AstraZeneca. AS reports lecture fees and prior study grants by Medtronic
and C.R. Bard. JBF reports receiving consulting, lecture and advisory board
fees by BMS, Siemens, Philips, Perceptive, Bio-Imaging Technologies,
Boehringer Ingelheim, Lundbeck and Sygnis.
Received: 4 July 2010 Accepted: 21 July 2010 Published: 21 July 2010
References
1. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU:
Epidemiology of ischemic stroke subtypes according to TOAST criteria:
incidence, recurrence, and long-term survival in ischemic stroke
subtypes: a population-based study. Stroke 2001, 32:2735-2740.
2. Montaner J, Perea-Gainza M, Delgado P, Ribo M, Chacon P, Rosell A,
Quintana M, Palacios ME, Molina CA, Alvarez-Sabin J: Etiologic diagnosis of
ischemic stroke subtypes with plasma biomarkers. Stroke 2008,
39:2280-2287.
3. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE:
Prevalence of diagnosed atrial fibrillation in adults: national implications
for rhythm management and stroke prevention: the AnTicoagulation
and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001,
285:2370-2375.
4. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH,
Stijnen T, Lip GY, Witteman JC: Prevalence, incidence and lifetime risk of
atrial fibrillation: the Rotterdam study. Eur Heart J 2006, 27:949-953.
5. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, Carolei A:
Contribution of atrial fibrillation to incidence and outcome of ischemic
stroke: results from a population-based study. Stroke 2005, 36:1115-1119.
6. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA,
Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, et al: ACC/AHA/ESC 2006
guidelines for the management of patients with atrial fibrillation: full
text: a report of the American College of Cardiology/American Heart
Association Task Force on practice guidelines and the European Society
of Cardiology Committee for Practice Guidelines (Writing Committee to
Revise the 2001 guidelines for the management of patients with atrial
fibrillation) developed in collaboration with the European Heart Rhythm
Association and the Heart Rhythm Society. Europace 2006, 8:651-745.
7. Chugh A, Morady F: Atrial fibrillation: catheter ablation. J Interv Card
Electrophysiol 2006, 16:15-26.
8. Lee SH, Tai CT, Hsieh MH, Tsai CF, Lin YK, Tsao HM, Yu WC, Huang JL,
Ueng KC, Cheng JJ, et al: Predictors of early and late recurrence of atrial
fibrillation after catheter ablation of paroxysmal atrial fibrillation. J Interv
Card Electrophysiol 2004, 10:221-226.
9. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH,
Klein G, Natale A, Packer D, et al: Updated worldwide survey on the
Haeusler et al. BMC Neurology 2010, 10:63
http://www.biomedcentral.com/1471-2377/10/63
Page 4 of 5methods, efficacy, and safety of catheter ablation for human atrial
fibrillation. Circ Arrhythm Electrophysiol 2010, 3:32-38.
10. Dagres N, Hindricks G, Kottkamp H, Sommer P, Gaspar T, Bode K, Arya A,
Husser D, Rallidis LS, Kremastinos DT, Piorkowski C: Complications of atrial
fibrillation ablation in a high-volume center in 1,000 procedures: still
cause for concern? J Cardiovasc Electrophysiol 2009, 20:1014-1019.
11. Spragg DD, Dalal D, Cheema A, Scherr D, Chilukuri K, Cheng A,
Henrikson CA, Marine JE, Berger RD, Dong J, Calkins H: Complications of
catheter ablation for atrial fibrillation: incidence and predictors. J
Cardiovasc Electrophysiol 2008, 19:627-631.
12. Bertaglia E, Brandolino G, Zoppo F, Zerbo F, Pascotto P: Integration of
three-dimensional left atrial magnetic resonance images into a real-time
electroanatomic mapping system: validation of a registration method.
Pacing Clin Electrophysiol 2008, 31:273-282.
13. van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL,
Hellemons BS, Koefed BG, Laupacis A: A clinical prediction rule to identify
patients with atrial fibrillation and a low risk for stroke while taking
aspirin. Arch Intern Med 2003, 163:936-943.
14. Lickfett L, Hackenbroch M, Lewalter T, Selbach S, Schwab JO, Yang A,
Balta O, Schrickel J, Bitzen A, Luderitz B, Sommer T: Cerebral diffusion-
weighted magnetic resonance imaging: a tool to monitor the
thrombogenicity of left atrial catheter ablation. J Cardiovasc Electrophysiol
2006, 17:1-7.
15. Schrickel JW, Lickfett L, Lewalter T, Mittman-Braun E, Selbach S, Strach K,
Nahle CP, Schwab JO, Linhart M, Andrie R, et al: Incidence and predictors
of silent cerebral embolism during pulmonary vein catheter ablation for
atrial fibrillation. Europace 2010, 12:52-57.
16. Klein G, Oswald H, Gardiwal A, Lusebrink U, Lissel C, Yu H, Drexler H:
Efficacy of pulmonary vein isolation by cryoballoon ablation in patients
with paroxysmal atrial fibrillation. Heart Rhythm 2008, 5:802-806.
17. Mansour M, Forleo GB, Pappalardo A, Heist EK, Avella A, Laurenzi F, De
Girolamo P, Bencardino G, Dello Russo A, Mantica M, et al: Initial
experience with the Mesh catheter for pulmonary vein isolation in
patients with paroxysmal atrial fibrillation. Heart Rhythm 2008,
5:1510-1516.
18. Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C,
Kottkamp H: Perception of atrial fibrillation before and after
radiofrequency catheter ablation: relevance of asymptomatic arrhythmia
recurrence. Circulation 2005, 112:307-313.
19. Hotter B, Pittl S, Ebinger M, Oepen G, Jegzentis K, Kudo K, Rozanski M,
Schmidt WU, Brunecker P, Xu C, et al: Prospective study on the mismatch
concept in acute stroke patients within the first 24 h after symptom
onset - 1000Plus study. BMC Neurol 2009, 9:60.
20. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J,
Holleran R, Eberle R, Hertzberg V, et al: Measurements of acute cerebral
infarction: a clinical examination scale. Stroke 1989, 20:864-870.
21. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J:
Interobserver agreement for the assessment of handicap in stroke
patients. Stroke 1988, 19:604-607.
22. Lezak MD: Neuropsychological Assessment New York: Oxford University Press,
4 2004.
23. Sturm W, Wilmes K, Horn W: Leistungsprüfsystem für 50-90jährige (LPS 50+)
Göttingen: Hogrefe 1993.
24. Helmstaedter C, Durwen HF: [The Verbal Learning and Retention Test. A
useful and differentiated tool in evaluating verbal memory
performance]. Schweiz Arch Neurol Psychiatr 1990, 141:21-30.
25. Lehrl S, Merz J, Erzigkeit H, Galster V: [MWT-A–a repeatable intelligence
short-test, fairly independent from psycho-mental disorders]. Nervenarzt
1974, 45:364-369.
26. Frayne R, Goodyear BG, Dickhoff P, Lauzon ML, Sevick RJ: Magnetic
resonance imaging at 3.0 Tesla: challenges and advantages in clinical
neurological imaging. Invest Radiol 2003, 38:385-402.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2377/10/63/prepub
doi:10.1186/1471-2377-10-63
Cite this article as: Haeusler et al.: Stroke risk associated with balloon
based catheter ablation for atrial fibrillation: Rationale and design of
the MACPAF Study. BMC Neurology 2010 10:63.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Haeusler et al. BMC Neurology 2010, 10:63
http://www.biomedcentral.com/1471-2377/10/63
Page 5 of 5